Erythroderma caused by apatinib combined with toripalimab
10.3760/cma.j.cn114015-20220721-00658
- VernacularTitle:阿帕替尼与特瑞普利单抗联用致红皮病
- Author:
Shuyi XUE
1
;
Xiaolin CHEN
;
Jing GONG
;
Guanmin ZHANG
;
Yanhua ZHANG
;
Yue YIN
Author Information
1. 北京大学肿瘤医院暨北京市肿瘤防治研究所药剂科，恶性肿瘤发病机制及转化研究教育部重点实验室，北京 100142
- Publication Type:Journal Article
- Keywords:
Apatinib;
Toripalimab;
Erythroderma;
Skin adverse reactions
- From:
Adverse Drug Reactions Journal
2023;25(8):508-510
- CountryChina
- Language:Chinese
-
Abstract:
A 66-year-old male patient with malignant melanoma received combined treatments with apatinib (oral 250 mg once daily), temozolomide (oral 500 mg on day 1 and 400 mg/d on days 2-4), toripalimab(240 mg intravenous infusion on days 1 and 15). After 5 cycles (28 days as a cycle), the patient developed multiple rashes, which were not alleviated after reducing the dose of apatinib to 250 mg orally once every 3 days in the 6th treatment cycle. Laboratory tests showed that serum albumin was 28.5 g/L, total serum protein was 55.5 g/L, eosinophil percentage was 0.096, and venous potassium was 3.17 mmol/L. Erythroderma caused by combination of apatinib and toripalimab was considered, and the 2 drugs were stopped. The patient received the treatments of methylprednisolone, loratadine, diphenhydramine, triamcinolone acetonide and econazole nitrate cream and mupirocin ointment (external coating), and skin care. At the same time, symptomatic treatments such as protein supplement, diuresis, potassium supplement, and stomach protection were given. After 10 days of treatments, the rash subsided, and desquamation and itching were improved.
